Related Experiment Video
Updated: Jun 13, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Direct-to-consumer genome testing: opportunities for pharmacogenomics research?
Barbara Prainsack1, Howard Wolinsky
1King's College London, Centre for Biomedicine & Society (CBAS), London, UK. barbara.prainsack@kcl.ac.uk
Abstract:
This commentary examines the role that commercial providers of SNP-based genome-wide personalized risk profiles play in facilitating pharmacogenomics research. We first take a look at how personal genomics services, exemplified by the company 23andMe, communicate information on drug response to customers. We then discuss the most important benefits and issues we see arising with the idea of 'crowdsourcing' pharmacogenomics research via commercial genome-scan providers. We conclude with a brief vision for the future.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Principles of Pharmacogenetics: Types of Genetic Variants

